Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EpiVacCorona
- Development stage
- Phase 3
- Lead developer
- State Research Center of Virology and Biotechnology Vector
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Peptides
- Administration
- Intramuscular
01
Overview
EpiVacCorona is a peptide-based vaccine developed by the State Research Center of Virology and Biotechnology VECTOR in Russia for the prevention of COVID-19. The vaccine contains three chemically synthesized short fragments (peptides) of the SARS-CoV-2 spike protein, each conjugated to a recombinant chimeric carrier protein that includes parts of the viral nucleocapsid protein and bacterial maltose-binding protein. These peptide-protein complexes are adsorbed onto an aluminum hydroxide adjuvant to enhance immune response. The mechanism of action involves stimulating an immune response against SARS-CoV-2 by presenting key viral epitopes to B-cells, thereby promoting antibody production. Clinical trials have shown that EpiVacCorona induces specific anti-coronavirus antibodies with minimal adverse reactions[1][3][4].
- Brand names
- EpiVacCorona
02
Targets
N (Nucleocapsid protein)SARS-CoV-2 spike
Beyond the preview
Go deeper on EpiVacCorona.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpiVacCorona.